In his second appearance on the show, Christopher Booth, MD, Professor in the Departments of Oncology and Medicine as well as a Health Services Researcher, Queen’s University (Canada), shares his unique career path and early considerations of conflicts of interest in the medical world, how the influences of pharma relationships are more subtle than expected, whether you can be a clinical trialist without working with pharma, and how the system can be changed to truly benefit patients. Additionally, Chadi and Dr. Booth hit on painpoints including patient enrollment, pharma-sponsored conference sessions, satellite symposiums, patient advocacy groups and advocacy societies, global relevancy of “suboptimal” control arms in clinical trials, and more.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
